ATE397665T1 - Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon - Google Patents
Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davonInfo
- Publication number
- ATE397665T1 ATE397665T1 AT94907045T AT94907045T ATE397665T1 AT E397665 T1 ATE397665 T1 AT E397665T1 AT 94907045 T AT94907045 T AT 94907045T AT 94907045 T AT94907045 T AT 94907045T AT E397665 T1 ATE397665 T1 AT E397665T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- lymphotoxin
- complexes
- cell
- alpha
- Prior art date
Links
- 102000003959 Lymphotoxin-beta Human genes 0.000 title abstract 5
- 108090000362 Lymphotoxin-beta Proteins 0.000 title abstract 5
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000002644 phorbol ester Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99030492A | 1992-12-04 | 1992-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE397665T1 true ATE397665T1 (de) | 2008-06-15 |
Family
ID=25536005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94907045T ATE397665T1 (de) | 1992-12-04 | 1993-12-02 | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0672143B1 (de) |
| JP (3) | JPH08507201A (de) |
| AT (1) | ATE397665T1 (de) |
| AU (1) | AU692146B2 (de) |
| CA (1) | CA2150249A1 (de) |
| DE (1) | DE69334224D1 (de) |
| HK (1) | HK1013835A1 (de) |
| WO (1) | WO1994013808A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286497B6 (sk) * | 1995-01-26 | 2008-11-06 | Biogen Idec Ma, Inc. | Zmes LT-alfa/beta heteromérneho komplexu a/alebo najmenej jedného LT-beta-R aktivujúceho činidla, farmaceutický prostriedok, LT-beta-R aktivujúce činidlo a spôsob jeho výberu |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US7078493B1 (en) | 1995-03-15 | 2006-07-18 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like genes |
| US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| US8110659B1 (en) | 1995-03-15 | 2012-02-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
| WO1996040774A1 (en) * | 1995-06-07 | 1996-12-19 | Biogen, Inc. | Complexes of modified lymphotoxins as pharmaceutical preparations |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| EA002983B1 (ru) * | 1996-10-25 | 2002-12-26 | Байоджен, Инк. | Способ изменения гуморального иммунного ответа с помощью агентов, блокирующих рецепторы бета-лимфотоксина |
| EP1723967A3 (de) * | 1996-10-25 | 2007-01-10 | Biogen Idec MA, Inc. | Lösliche Lymphotoxin-beta Rezeptoren, Antikörper gegen Lymphotoxin und Antikörper gegen Lymphotoxinligand als therapeutische Agenzien zur Behandlung immunogischer Krankheiten |
| US7255854B1 (en) | 1996-10-25 | 2007-08-14 | Biogen, Inc. | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases |
| US6998108B1 (en) * | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
| US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| EP1119370B1 (de) | 1998-10-09 | 2006-06-14 | Biogen Idec MA Inc. | Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges |
| IL155340A0 (en) | 2000-10-13 | 2003-11-23 | Biogen Inc | HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES |
| CN1678625A (zh) | 2002-07-01 | 2005-10-05 | 比奥根艾迪克Ma公司 | 人源化抗淋巴毒素β受体的抗体 |
| JP2006515750A (ja) * | 2002-12-20 | 2006-06-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療 |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| EP1756162A1 (de) | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Rezeptor-kupplungsmittel und ihre therapeutischen verwendungen |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2006114284A2 (en) * | 2005-04-25 | 2006-11-02 | Pluta Rechtsanwalts Gmbh | AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY |
| SG178002A1 (en) | 2006-10-20 | 2012-02-28 | Biogen Idec Inc | Treatment of demyelinating disorders |
| US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2157889T3 (es) * | 1990-06-27 | 2001-09-01 | Biogen Inc | Linfotoxina complejada de superficie. |
-
1993
- 1993-12-02 DE DE69334224T patent/DE69334224D1/de not_active Expired - Fee Related
- 1993-12-02 WO PCT/US1993/011669 patent/WO1994013808A2/en active Application Filing
- 1993-12-02 JP JP6514235A patent/JPH08507201A/ja not_active Withdrawn
- 1993-12-02 AT AT94907045T patent/ATE397665T1/de not_active IP Right Cessation
- 1993-12-02 EP EP94907045A patent/EP0672143B1/de not_active Expired - Lifetime
- 1993-12-02 AU AU60483/94A patent/AU692146B2/en not_active Ceased
- 1993-12-02 CA CA002150249A patent/CA2150249A1/en not_active Abandoned
-
1998
- 1998-12-17 HK HK98113963A patent/HK1013835A1/xx not_active IP Right Cessation
-
2003
- 2003-11-12 JP JP2003383099A patent/JP2004135676A/ja not_active Withdrawn
-
2006
- 2006-09-19 JP JP2006253541A patent/JP2007039464A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0672143A1 (de) | 1995-09-20 |
| HK1013835A1 (en) | 1999-09-10 |
| WO1994013808A3 (en) | 1994-08-04 |
| WO1994013808A2 (en) | 1994-06-23 |
| EP0672143B1 (de) | 2008-06-04 |
| CA2150249A1 (en) | 1994-06-23 |
| JPH08507201A (ja) | 1996-08-06 |
| DE69334224D1 (de) | 2008-07-17 |
| JP2004135676A (ja) | 2004-05-13 |
| AU6048394A (en) | 1994-07-04 |
| JP2007039464A (ja) | 2007-02-15 |
| AU692146B2 (en) | 1998-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE397665T1 (de) | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon | |
| DK0536299T3 (da) | Overfladekompleksbundet lymfotolksin | |
| Shin et al. | IN VIVO EXPRESSION OF TRANSFORMING GROWTH FACTOR-β1 IN HUMANS: Stimulation by Cyclosporine: 1 | |
| Dinarello | Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzyme a | |
| Powis et al. | Properties and biological activities of thioredoxins | |
| Zhang et al. | Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. | |
| Goldstein | History of the discovery of the thymosins | |
| BG60256B1 (bg) | Рекомбинантен метод за получаване на лимфотоксин | |
| ATE259828T1 (de) | Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel | |
| KR900700592A (ko) | 용해성 티-4 유도체 | |
| SE9002589D0 (sv) | Neutrofil-aktiverande peptid-2 | |
| EP0107498A2 (de) | Synergistische Humaninterferonaktivität | |
| Shearer et al. | Regulation of cell growth by interferon | |
| Takane et al. | Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice | |
| Barbanti-Brodano et al. | Selective killing of macrophages by amanitin-albumin conjugates | |
| KR900005994A (ko) | 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제 | |
| ATE352556T1 (de) | Zytomodulierende lipophile peptide zur modulation der immunsystemaktivität und hemmung von entzündungen | |
| Sehgal et al. | Interferon and its inducers | |
| Ortaldo et al. | Augmentation of human natural killer cells with human leukocyte and human recombinant leukocyte interferon | |
| ATE292173T1 (de) | Lipidspaltender enzymkomplex | |
| Higgins et al. | Interleukin-1 Inhibitors and Their Significance in Rheumatoid Arthritis | |
| Persico | Low molecular weight inhibitors of interleukin-1 | |
| Gewert et al. | The effect of interferon on cells deficient in nucleoside transport or lacking thymidine kinase activity | |
| McEntire et al. | Biochemical characterization of a macrophage activating lymphokine | |
| Iida et al. | An improved noninfections murine skin model of organized granulomatous inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |